The bioavailability of Tamoplex® (tamoxifen)
- 114 Downloads
The bioavailability of two tamoxifen preparations (Tamoplex® and Nolvadex®) was compared in a multiple dose two-way cross-over design in twelve breast cancer patients. The formulations were found to be bioequivalent. Mean steady-state serum levels of tamoxifen andN-desmethyltamoxifen were 133 ng/ml and 242 ng/ml, respectively, at a single daily dose of three tablets of Tamoplex® 10 mg and 128 ng/ml and 248 ng/ml, respectively, at a single daily dose of three tablets of Nolvadex® 10 mg. While there was a large interpatient as well as intrapatient variability in steady-state levels of tamoxifen andN-desmethyltamoxifen, their ratio appeared to be constant in the individual patient.
Key wordsBioavailability Breast neoplasms Drug evaluation Tamoxifen
Unable to display preview. Download preview PDF.
- 2.Patterson JS, Settatree RS, Adam HK, Kemp JV. Serum concentrations of tamoxifen and major metabolite during long-term Nolvadex therapy, correlated with clinical response. In: Mouridsen H, Palshof T, eds. Breast cancer: experimental and clinical aspects. London: Pergamon, 1980:89–92.Google Scholar
- 7.Soininen K, Kleimola T, Elomaa I, Salmo M, Rissanen P. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients. J Int Res 1986;14:162–5.Google Scholar
- 8.Metzler CM, Huang DC. Statistical methods for bioavailability and bioequivalence. Clin Res Pract Drug Reg Affairs 1983;1:109–32.Google Scholar
- 10.Spriet A, Beiler D. Table to facilitate determination of symmetrical confidence intervals in bioavailability trials with Westlake's method. Eur J Drug Metab Pharmacokinet 1978;2:129–32.Google Scholar